Identification of Novel Therapeutic Approaches for pHGGs

Email Principal Investigator
Ongoing
Data
HGG
LGG

About this

Project

Gliomas are the most common central nervous system (CNS) tumors in children and adolescents, and they display a particularly broad range of clinical behavior. The impact of CNS tumors on infant mortality is very important. During the last decades there have been no advances in the prognosis of these tumors, while therapeutic strategies have changed very little. The majority of pediatric gliomas develop as benign, slow-growing lesions classified as grade I or II by the WHO classification of CNS tumors and among these, pilocytic astrocytoma accounts for ∼20% of all pediatric brain tumors. However, a substantial portion of gliomas develop over a short period of time and progress rapidly and are therefore classified as WHO grade III or IV high-grade gliomas (HGGs). Pediatric high-grade glioma (pHGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis, with the most aggressive forms being lethal within months.

Ask The

Scientists

Ask the scientists

What are the goals of this project?

Conventional treatments, such as chemotherapy and radiotherapy, have devastating effects on the developing brain of a child. Hence, novel treatment modalities are desperately needed. We are planning to use a combination of mouse and patient-derived models to identify novel therapeutic approaches for pHGGs.

Explore the data in these informatics portals

Cavativa-Logo.png